Entering text into the input field will update the search result below

Private equity firm prepares for exit with Par Pharma IPO

Mar. 13, 2015 8:00 AM ETPar Pharmaceutical Companies, Inc. (PRX) StockPRXBy: Douglas W. House, SA News Editor
  • Private equity firm TPG Capital prepares to exit from its $1.9B buyout of Par Pharmaceutical Holdings (NYSE:PRX) in 2012 with the filing of an S-1 for a $100M IPO.
  • The company sells a portfolio of 95 high-barrier-to-entry generic drugs that are characterized by being more difficult to formulate and manufacture or face complex legal or regulatory challenges. It operates in two business segments: Par Pharmaceutical, which sells the generic line and Par Specialty Pharmaceuticals, which sells two branded products.
  • 2014 Financial Performance ($M): Total Revenues: 1,308.9 (+19.2%); Net Product Sales: 1,278.1 (+20.3%); Gross Margin: 479.1 (+50.7%); Gross Margin: 36.6% (+26.2%); Operating Expenses: 542.7 (+41.5%); Net Loss: (105.5) (+0.4%); Loss Per Share: (0.14) (+6.7%); CF Ops: 145.2 (+28.5%); Non-GAAP EBITDA: 433.8 (+41.3%).

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
PRX--
Par Pharmaceutical Companies, Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.